Literature DB >> 31509514

Aggressive treatment for urothelial cancer-complete urinary tract extirpation: Operative feasibility in two cases.

Murat Akand1, Özcan Kılıç1, İsmail Harmankaya2, Pınar Karabağlı2, Çağdaş Yavaş3, Özlem Ata4.   

Abstract

Bladder cancer (BC), the most common malignancy of the urinary tract, accounts for 90-95% of all urothelial carcinomas (UCs), while upper urinary tract UC (UUTUC) accounts for only 5-10%. Radical nephroureterectomy with excision of bladder cuff, and radical cystectomy with pelvic lymph node dissection and a urinary diversion (UD) are the gold standard treatments for UUTUC and muscle-invasive bladder cancer (MIBC), respectively. These two treatments can be performed simultaneously when a bilateral or unilateral UUTUC is present with a MIBC, and are called complete urinary tract extirpation (CUTE) and hemi-CUTE, respectively. This complex surgery can help the patient by avoiding multi-staged surgeries, repeated anesthesia, and delay in completion of treatment. Herein, we report the first cases of a hemi-CUTE and CUTE in our department and share our experience with this aggressive and complex surgical treatment.

Entities:  

Year:  2018        PMID: 31509514      PMCID: PMC6739080          DOI: 10.5152/tud.2018.55453

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  17 in total

1.  [Preventive prepubic urethrectomy].

Authors:  H Van Poppel; S Joniau; G Bogaert
Journal:  Aktuelle Urol       Date:  2010-03-22       Impact factor: 0.658

2.  Single-session laparoscopic total urinary tract exenteration without repositioning for multifocal urothelial carcinoma in dialysis-dependent patients.

Authors:  Victor Chia-Hsiang Lin; Kuo-Chuan Hung; Ming-Jenn Chen; Kevin Lu; Yuchi Chen; Hui-Chin Weng; Tsan Jung Yu
Journal:  Urology       Date:  2011-01       Impact factor: 2.649

3.  Complete urinary tract extirpation: the University of Maryland experience.

Authors:  Mara R Holton; P Sean Van Zijl; W Todd Oberle; Stephen C Jacobs; Geoffrey N Sklar
Journal:  Urology       Date:  2006-06-27       Impact factor: 2.649

4.  Complete urinary tract exenteration for a dialysis patient with urothelial cancer: lower midline and extraperitoneal approach in a supine position.

Authors:  Chien-Hui Ou; Wen-Horng Yang
Journal:  Urology       Date:  2011-02-18       Impact factor: 2.649

5.  Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma.

Authors:  Ching-Fang Wu; Jia-Jen Shee; Dong-Ru Ho; Wen-Chung Chen; Chih-Shou Chen
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

Review 6.  Urinary diversion.

Authors:  Richard E Hautmann; Hassan Abol-Enein; Khaled Hafez; Isao Haro; Wiking Mansson; Robert D Mills; James D Montie; Arthur I Sagalowsky; John P Stein; Arnulf Stenzl; Urs E Studer; Bjoern G Volkmer
Journal:  Urology       Date:  2007-01       Impact factor: 2.649

7.  Simultaneous laparoscopic nephroureterectomy and cystectomy: a preliminary report.

Authors:  Rodrigo Barros; Rodrigo Frota; Robert J Stein; Burak Turna; Inderbir S Gill; Mihir M Desai
Journal:  Int Braz J Urol       Date:  2008 Jul-Aug       Impact factor: 1.541

8.  Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

9.  Laparoscopic complete urinary tract exenteration with the specimen withdrawn transvaginally.

Authors:  Ching-Chia Li; Hsun-Shuan Wang; Wen-Jeng Wu; Yii-Her Chou; Chia-Chu Liu; Cheng-Yu Long; Shih-Cheng Hus; Chieh-Han Chuang; Mei-Yu Jang; Shu-Pin Huang; Yung-Shun Juan; Chun-Hsiung Huang
Journal:  BJU Int       Date:  2009-01-19       Impact factor: 5.588

10.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.